首页|药品上市后变更风险控制的探讨

药品上市后变更风险控制的探讨

扫码查看
目的 本文根据药品法规的要求,研究探讨药品在上市后发生变更时如何进行风险控制,为药品生产企业变更风险管理提供参考.方法 围绕人、机、料、法、环、以及药政法规多个方面进行风险分析,制定控制措施.结果 经过风险分析,制定人员培训、对仪器设备进行确认、修订文件、对生产环境进行确认、按药政法规要求申报变更等措施.结论 药品上市许可持有人和生产企业是药品上市后变更管理的责任主体,应当建立变更控制体系,对发生的变更进行分类、风险评估、制定控制风险措施以及研究验证工作,将药品质量风险降至最低.
Discussion on the Risk Control of Post-Marketing Drug Changes
OBJECTIVE In accordance with drug regulatory requirements,this article studiedand exploredhow to conduct risk control when drugs changed after post-marketing,to providereference for risk management of changes in drug production enterprises.METHODS Conducted risk analysis and developed control measures around multi-ple aspects such as human,machine,material,method,environment,and pharmaceutical regulations.RESULTS Af-ter risk analysis,the measures such as personnel training,instrument and equipment validation,document revision,production environment validation,and reporting changes in accordance with pharmaceutical regulations have been formulated.CONCLUSION Drug marketing license holders and manufacturing enterprises are the responsible sub-jects of post-marketing change management of drugs,and should establish a Change control system to classify,assess risks,develop risk control measures,and conduct research and verification to minimize drug quality risks.

Changesafter drug post-marketingChange riskRisk Management

王洁、陈红英

展开 >

广州白云山明兴制药有限公司,广东广州 510250

药品上市后变更 变更风险 风险控制

2024

海峡药学
中国药学会福建分会

海峡药学

影响因子:0.643
ISSN:1006-3765
年,卷(期):2024.36(5)